CXCL13 and osteosarcoma: Treatment of human osteosarcoma cell lines (MG-63, HOS, and U2OS) with CXCL13 (3–30 ng/mL) concentration-dependently facilitated migratory and invasive abilities (Figure 1A,B), but did not affect the viability of osteosarcoma cells (Figure 1C).